当前位置: X-MOL 学术Blood Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2021-12-01 , DOI: 10.1038/s41408-021-00580-7
Saemundur Rognvaldsson 1, 2 , Elias Eythorsson 2 , Sigrun Thorsteinsdottir 1, 3 , Brynjar Vidarsson 2 , Pall Torfi Onundarson 1, 2 , Bjarni A Agnarsson 1, 2 , Margret Sigurdardottir 2 , Ingunn Thorsteinsdóttir 2 , Isleifur Olafsson 1, 2 , Hrafnhildur L Runolfsdottir 2 , Dadi Helgason 2 , Arna R Emilsdottir 2 , Arnar S Agustsson 1, 2 , Aron H Bjornsson 1, 2 , Gudrun Kristjansdottir 2 , Asdis Rosa Thordardottir 1 , Olafur Skuli Indridason 1, 2 , Asbjorn Jonsson 4 , Gauti Kjartan Gislason 1 , Andri Olafsson 1 , Hlif Steingrimsdottir 2 , Petros Kampanis 5 , Malin Hultcrantz 6 , Brian G M Durie 7 , Stephen Harding 5 , Ola Landgren 8 , Runolfur Palsson 1, 2 , Thorvarður Jon Love 1, 2 , Sigurdur Yngvi Kristinsson 1, 2
Affiliation  

Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.



中文翻译:

意义不明的单克隆丙种球蛋白病和 COVID-19:一项基于人群的队列研究

多发性骨髓瘤 (MM) 患者在感染严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 时患严重冠状病毒病 2019 (COVID-19) 的风险增加。意义未定的单克隆丙种球蛋白病 (MGUS) 是 MM 的前体,与可能导致严重 COVID-19 的免疫功能障碍有关。尚未发表关于 MGUS 患者 COVID-19 的系统数据。我们进行了一项基于人群的大型队列研究,评估 MGUS 患者感染 SARS-CoV-2 和严重 COVID-19 的风险。我们纳入了 1976 年之前出生的 75,422 名冰岛人,他们在冰岛筛查治疗或预防多发性骨髓瘤研究 (iStopMM) 中接受了 MGUS 筛查。SARS-CoV-2 检测和 COVID-19 严重程度的数据来自冰岛 COVID-19 研究组。使用测试阴性研究设计,我们纳入了 32,047 名接受过 SARS-CoV-2 检测的 iStopMM 参与者,其中 1754 人患有 MGUS。在这些参与者中,1100 名参与者检测呈阳性,其中 65 人患有 MGUS。230 名参与者出现了严重的 COVID-19,其中 16 名患有 MGUS。MGUS 与 SARS-CoV-2 感染无关(优势比(OR):1.05;95% 置信区间(CI):0.81-1.36;p  = 0.72)或重症 COVID-19(OR:0.99;95%CI:0.52–1.91;p  = 0.99)。这些发现表明 MGUS 不会影响对 SARS-CoV-2 的易感性或 COVID-19 的严重程度。

更新日期:2021-12-02
down
wechat
bug